首页> 外文期刊>BMC Cancer >Displayed correlation between gene expression profiles and submicroscopic alterations in response to cetuximab, gefitinib and EGF in human colon cancer cell lines
【24h】

Displayed correlation between gene expression profiles and submicroscopic alterations in response to cetuximab, gefitinib and EGF in human colon cancer cell lines

机译:在人类结肠癌细胞系中,对西妥昔单抗,吉非替尼和EGF的应答,基因表达谱与亚显微改变之间显示相关性

获取原文
           

摘要

Background EGFR is frequently overexpressed in colon cancer. We characterized HT-29 and Caco-2, human colon cancer cell lines, untreated and treated with cetuximab or gefitinib alone and in combination with EGF. Methods Cell growth was determined using a variation on the MTT assay. Cell-cycle analysis was conducted by flow cytometry. Immunohistochemistry was performed to evaluate EGFR expression and scanning electron microscopy (SEM) evidenced the ultrastructural morphology. Gene expression profiling was performed using hybridization of the microarray Ocimum Pan Human 40 K array A. Results Caco-2 and HT-29 were respectively 66.25 and 59.24 % in G0/G1. They maintained this level of cell cycle distribution after treatment, suggesting a predominantly differentiated state. Treatment of Caco-2 with EGF or the two EGFR inhibitors produced a significant reduction in their viability. SEM clearly showed morphological cellular transformations in the direction of cellular death in both cell lines treated with EGFR inhibitors. HT-29 and Caco-2 displayed an important reduction of the microvilli (which also lose their erect position in Caco-2), possibly invalidating microvilli absorption function. HT-29 treated with cetuximab lost their boundary contacts and showed filipodi; when treated with gefitinib, they showed some vesicles: generally membrane reshaping is evident. Both cell lines showed a similar behavior in terms of on/off switched genes upon treatment with cetuximab. The gefitinib global gene expression pattern was different for the 2 cell lines; gefitinib treatment induced more changes, but directly correlated with EGF treatment. In cetuximab or gefitinib plus EGF treatments there was possible summation of the morphological effects: cells seemed more weakly affected by the transformation towards apoptosis. The genes appeared to be less stimulated than for single drug cases. Conclusion This is the first study to have systematically investigated the effect of cetuximab or gefitinib, alone and in combination with EGF, on human colon cancer cell lines. The EGFR inhibitors have a weaker effect in the presence of EGF that binds EGFR. Cetuximab treatment showed an expression pattern that inversely correlates with EGF treatment. We found interesting cyto-morphological features closely relating to gene expression profile. Both drugs have an effect on differentiation towards cellular death.
机译:背景EGFR在结肠癌中经常过表达。我们表征了未经治疗的西妥昔单抗或吉非替尼单独治疗以及与EGF结合治疗的人结肠癌细胞HT-29和Caco-2。方法使用MTT法检测细胞生长情况。通过流式细胞术进行细胞周期分析。进行了免疫组织化学以评估EGFR的表达,并且扫描电子显微镜(SEM)证明了超微结构形态。使用微阵列Ocimum Pan Human 40 K阵列A进行杂交,进行基因表达谱分析。结果Caco-2和HT-29在G0 / G1中分别为66.25%和59.24%。他们在治疗后保持了这一水平的细胞周期分布,表明处于主要分化状态。用EGF或两种EGFR抑制剂处理Caco-2会大大降低其生存能力。 SEM清楚地显示了在用EGFR抑制剂处理的两种细胞系中细胞死亡方向上的形态学细胞转化。 HT-29和Caco-2表现出微绒毛的显着减少(它们也失去了在Caco-2中的直立位置),可能使微绒毛的吸收功能失效。西妥昔单抗治疗的HT-29失去边界接触并显示出filipodi。当用吉非替尼治疗时,它们显示出一些囊泡:通常膜重塑是明显的。在用西妥昔单抗治疗后,两种细胞系在开/关转换基因方面均表现出相似的行为。两种细胞系的吉非替尼整体基因表达模式不同;吉非替尼治疗可引起更多变化,但与EGF治疗直接相关。在西妥昔单抗或吉非替尼加EGF的治疗中,可能会总结出形态学影响:细胞似乎更容易受到细胞凋亡的影响。该基因似乎比单药病例受到的刺激更少。结论这是第一项系统研究西妥昔单抗或吉非替尼单独或与EGF联合使用对人结肠癌细胞系的影响的研究。在结合EGFR的EGF存在下,EGFR抑制剂的作用较弱。西妥昔单抗治疗显示出与EGF治疗成反比的表达模式。我们发现有趣的细胞形态特征与基因表达谱密切相关。两种药物都对分化成细胞死亡有影响。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号